Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Aims of channelopathies lecture
- Channelopathies in the genomic era
- What is an ion channel?
- Classical channelopathy: hyperekplexia
- Life and times of an ion channel in 5 steps
- Step 1: transcription
- Step 1: a theoretical image
- Step 1 example (1)
- Step 1 example (2)
- Step 2: splicing
- Step 2 mRNA processing: NMD
- NMD in CLCN1/ClC-1 myotonia congentia
- NMD in SCN1A/Nav1.1
- A digression: what is a missense mutation?
- Is missense mutation causing a disease?
- Translation to folding
- Step 3: protein processing
- Episodic ataxia type 1
- Step 4: localisation
- GABAA receptors in epilepsy
- Loss-of-function GABAA receptor mutation
- Step 5: degradation
- A word about ubiquitin
- SCA6 and Ca2+ channels
- The future of channelopathies
- Final word
Topics Covered
- Channelopathies in the Genomic Era
- Introduction to ion channels
- The example of Hyperekplexia
- Transcriptional regulation defects of ion channels are associated with cases of schizophrenia and epilepsy
- Ion channels mRNA processing in myotonia congentia and epilepsy
- Ion channel misfolding and episodic ataxia type 1
- Ion channel mistrafficking and epilepsy
- Ion channel degradation and Spinocerebellar ataxia type 6
- concluding remarks
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Schorge, S. (2014, July 1). Functional insights from genetic channelopathies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/IJVE1902.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Stephanie Schorge has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
I'm Stephanie Schorge, and I am
at the Royal Society University
Research Fellow working
here in the Department
of clinical and
experimental epilepsy
at the UCL Institute of Neurology.
And I'm going to talk today
about some functional insights
we have from human
genetic channelopathies
and how we think they
are linked to disease.
0:21
So the aim of this lecture, to
begin with, is to first of all,
give you an overview
of what channelopathies
are without giving an entire list.
And then I'm going to give an
overview of how genes are made
into ion channels
in five easy steps.
And for each of
those steps I'm going
to illustrate with
a specific example
of a particular channelopathy
that I've carefully
cherry picked to
focus in on one step.
And there are many, many other
channelopathies that I won't
mention, but the ones
that I do mention
are going to be those that
I have tried to isolate
specifically to
highlight those steps.
0:52
So we're in the genomic era.
And that makes life
much, much easier
for people who link ion
channels to diseases.
And this means that at this point,
finding a mutation in an ion
channel is less about finding
the gene and more just about
sequencing ion channels.
And the reason that most ion
channel-related diseases have
a neurological component is not
because neurons have all the ion
channels, but just that neurons
have most of the ion channels.
All cells, all living
cells have ion channels,
and you can almost
define a living cell
by the presence of ion channels.
And neurons in particular not just
because they have ion channels,
but because just about every ion
channel you have is in some neuron
somewhere.
So if you have a mutation
in an ion channel genes,
there's a very high
probability it's going
to affect some neuron somewhere.
So in the original incarnation,
because people who study ion
channels frequently have
been biophysicists who
look at the functioning
of intact channels,
our first conception was to find
these mutations in ion channel
genes and to express those and
to look at the channelopathy
as a change in the function
of an intact channel
with one amino acid changed, or
one or two inserted or deleted.
However, since we've entered this
era of vast amounts of sequencing,
we realize that many
channelopathies, if not most
channelopathies, they don't
just disrupt a single nucleotide
and a single amino acid, but they
will change the product of the gene
before the mRNA, the protein, ever
gets made and into the membrane
where the channel
would normally work.
And as I'll try to link to
throughout this lecture,
the treatments that we have
for diseases associated
with channelopathies are just
beginning to recognize that we may
not be treating a
channel in the membrane.
We may be treating an RNA
before it becomes a channel.